Most patients with disorders of gut-brain interaction receive pharmacotherapy with major or moderate drug-gene interactions.

ABSTRACT:

Background

How variations predicted by pharmacogenomic testing to alter drug metabolism and therapeutic response affect outcomes for patients with disorders of gut- brain interaction is unclear.

Aims

To assess the prevalence of pharmacogenomics-predicted drug-gene interactions and symptom outcomes for patients with disorders of gut-brain interaction.

Methods

Patients who were treated in our clinical practice for functional dyspepsia/bowel disorder underwent pharmacogenomic testing. The change in symptoms from baseline to 6 months was compared for patients with variations in CYP2D6 and CYP2C19, which metabolize neuromodulators, and SLC6A4, which encodes the sodium- dependent serotonin transporter.

Results

At baseline, 79 of 94 participants (84%) had at least one

SUBMITTER: Varma R 

PROVIDER: S-EPMC12523929 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature